喬石瑞先生是一位擁有 30 多年生物技術從業經驗的行業先鋒。 1981 年，喬石瑞先生加入了位於美國舊金山的基因泰克公司，從此開始他傳奇的一生。在基因泰克公司，喬石瑞先生成功的帶領同事實現了胰島素和重組人生長激素的商業化生産。這兩種藥物是首批獲得美國 FDA 認證的藥物。
此外，喬石瑞先生參加了 Serono S.A.（現屬於默克公司）公司北美工廠的創建工作；作爲副總裁，參與美國加利福尼亞兩家生物醫藥公司 Cholestech 和 Telios Pharmaceuticals 的創建工作。
喬石瑞先生擁有聖地哥亞大學化學工程學士學位，以及聖地哥亞州立大學 MBA 碩士學位。
林女士是美國 TLC 慈善基金會的主席和創始人，該基金會 2006 年成立於加利福尼亞，基金主要支持需要幫助的學生，資助他們順利完成學業。
林女士是一個特別有愛心的人，夢想著能夠用自己的行動，完成喜康公司以及 TCL 基金會的使命，向需要幫助的人提供幫助，建立一個美好的家園。
1987-2009 年，林女士任職于基因泰克公司，先後在多個部門擔任重要工作，例如GMP管理系統、臨床藥物生産部門、臨床藥物包裝部門、商業化藥物包裝部門以及生物化學工程部。 2009-2012 年，林女士擔任 Eusol 生物技術有限公司工廠經理，管理工廠藥物生産。林女士擁有藥學學士學位，並獲得台灣職業藥師資格。
Andreas Nechansky, Ph.D. VP of Research and Analytical Operations
Dr. Andreas Nechansky has more than 15 years of experience in the biotech industry and his last position was Chief Operating Officer of a GMP certified analytical service provider. His experience lies within the field of analytical characterization of Biopharmaceuticals and Biosimilars with a strong focus on Bioassays. Andreas’ vision is to build up a unique team by sharing his expertise and knowledge allowing JHL to deliver world-class Biosimilars to the people in need.
Andreas started his career as a postdoctoral fellow at Novartis followed by a position as Research Associate at The Scripps Research Institute. Next he joined the Igeneon/Aphton Biotech company as the Head of Assay Development focusing on developing and clinically profiling monoclonal anti-cancer antibodies. He then co-founded VelaLabs and was responsible for Analytical Operation and Business Development.
Andreas has received a Ph.D. degree in Molecular Biology from the University of Vienna, Austria. He has published papers in the area of allergy and oncology and on analytical characterization of antibodies. He is also the inventor of two patents.
KC Carswell, Ph.D. VP of Process Development
Dr. KC Carswell is the Vice President of Process Development at JHL Biotech. KC joined the company in 2012 as a founding member of the JHL team, and played an important role in the design of JHL’s clinical-scale Taiwan facility and commercial-scale China site.
Prior to joining JHL, KC was a Principal Engineer at Genentech, leading teams in Process Development and Manufacturing Sciences. KC assisted in development of next generation processes for several blockbuster products, and has also lead the transfer of commercial manufacturing processes to new facilities around the world.
Dr. Carswell is a Chemical Engineer and holds a B.S. from The University of Texas and a Ph.D. from Northwestern University.
WeiDong Cui, Ph.D. VP of Manufacturing and Technology
Dr. Weidong Cui has Over 20 years of experiences in Biotechnology Industry, leading teams in Process Development, Manufacturing and CMC Operation of therapeutic and prophylactic biologics.
Dr. Cui joined JHL Biotech from Chempartner, Shanghai, China where he served as an Executive Director/Deputy General Manager. Prior to Chempartner, Dr Cui had worked over 16 years at MedImmune LLC, Gaithersburg, MD, USA and played a number of leadership roles in Process Development, Manufacturing Sciences and Commercial Manufacturing Operation.
Dr. Cui received a Ph.D. degree in Microbiology from Syracuse University and was a postdoctoral fellow in Pharmaceutical Chemistry at University of California, San Francisco, CA.
Sohail Qureshi VP of Quality
Sohail Qureshi is the Vice President of Quality at JHL Biotech. Sohail has over 20 years cGMP quality leadership experience in biotechnology industry including development and deployment of quality systems and business processes to ensure regulatory compliance and business needs.
Sohail is a certified ISO 9001:2008 and cGMP lead auditor.
Prior to joining JHL, Sohail has worked at Genentech (San Francisco and Singapore), Imclone/Eli Lilly, MONSANTO, and NovoNordisk/Novozymes (North America) within various quality functions including both QA and QC.
Peter Pang, Ph.D. Sr. Director of Regulatory Affairs and Clinical Operations
Dr. Pang joined JHL Biotech in November 2014, he now serves as the Vice President of Regulatory Affairs and Clinical Operations. Prior to joining JHL Biotech in 2014, Dr. Pang was Director, Regulatory Affairs at 159 Antiaging Center Ltd, a biotech company developing cell based regenerative therapy. From 2008 to2013, he was General Manager, Scientific Affairs and later Assistant Director, Regulatory Affairs at New B Innovation Ltd where he directed the nonclinical development and regulatory programs for human and veterinary oxygen carrying therapeutics. Dr. Pang received his Ph.D. in Chemical Engineering and B.A. Sc. in Chemical Engineering/Chemistry from the University of British Columbia. He then joined the Michael Smith Laboratories, the University of British Columbia as a Postdoctoral Fellow. Dr. Pang has over twelve years of diverse drug development and regulatory experience.
何愈博士藥物開發法規暨化學製造管制 - 資深處長
Fred Shaw Director of Engineering Projects and Taiwan Validation
Fred Shaw is the Director of Engineering Projects and Validation at JHL Biotech Taiwan. Prior to joining JHL, he was the Deputy Director, Engineering Division of L & K Engineering Co., Ltd., which is an expert of Cleanroom and Facility Provider for hospital and pharmaceutical plants. He has more than 40 years of experience in Engineering, Construction and Project Management of local and overseas projects within large Consultant Companies in Taiwan including CTCI Corporation and L & K Engineering Co., Ltd.
Fred holds a M.S. degree in mechanical engineering from Marquette University, Wisconsin and is a registered professional mechanical engineer in Taiwan.
WeeLim GohDirector of Facility Inspection and Taiwan Engineering
WeeLim Goh is the Director of Facility and Engineering at JHL Biotech. In this role, he is responsible for JHL’s corporate facility and engineering in support of manufacturing. Prior to joining, he was Senior Manager - Engineering and Maintenance at Roche Singapore.
WeeLim has over 17 years of Engineering and Maintenance leadership experience in the life science industry. He has held various positions of increasing managerial responsibilities in different Biotechnology and Pharmaceutical companies including Merck Shape & Dohme, Edwards Lifesciences and Roche.
He received his B.Eng. degree with honors in Mechanical Engineering from Loughborough University of Technology and his M.B.A. degree from The Adelaide University.
Jill Liu, CPA(US) CIA MBA LLM Financial Controller
Jill 從 PriceWaterhouseCoopers 的財務審計師和內部控制顧問的職位問開始了她的職業生涯。她還從法國巴黎銀行的工作經驗獲得對財務運作的深刻理解。自2003年以來，Jill 主要服務於數個初創公司，包括在曼谷上市的 IT 硬體製造商 Cal-comp 和在互聯網/移動服務提供者 Rockmobile 擔任財務部門的主管。
Jill 是在美國華盛頓州註冊的註冊會計師。她在英國 Bradford 大學管理學院獲得工商管理碩士學位。
鄭子榮 博士 工藝研發副總裁﹝武漢﹞
James Chang Senior Director of Quality Assurance (Wuhan)
James Chang is the Director of Quality Assurance (QA) at JHL Biotech’s Wuhan site.
James has over 20 years of quality, manufacturing, validation and general management experience in the pharmaceutical industry. He has worked within various companies including Schering-Plough, Merck Sharpe & Dohme, Pfizer and Novartis in both Singapore and China.
James received his B.Eng. (Hons) in Chemical Engineering from National University of Singapore.
Michael Xie, Ph.D. Senior Director and Head of Quality Control (Wuhan)
Michael Xie is the Senior Director and Head of Quality Control at JHL Wuhan (XiKang).
Michael had years of experience as a leader in quality control and analytical development of monoclonal antibodies (mAbs), glycoprotein therapeutics, and related biological field; he also had extended experience in leading team and supervision of scientists, lab equipment and projects, including helped set up GMP protein analytical labs and GLP forensic testing labs.
Prior to joining JHL, Michael was Executive Director, Protein Analytics and QC at Suzhou Suncadia Biopharmaceuticals, a subsidiary of Hengrui Medicine; and before that he was Senior Director, Protein Analytical Sciences at WuXi AppTec Biopharmaceuticals. Before returning to China at 2014, Michael had tremendous US experience in biotech field as he was Director, Protein Analytics and Characterization at KPI Biopharma and senior scientist experience at Waters Corporation and University of Minnesota.
He graduated with Ph.D. of Chemistry at Trinity College, University of Dublin in Ireland.
Henry WuDirector of Corporate Projects and Engineering and Validation (Wuhan)
Henry Wu joined JHL in July 2016 as the Director of Corporate Projects, Wuhan Engineering and Validation.
Henry has extensive engineering and project management experience in the pharmaceutical industry, focused on project and process engineering, system retrofitting, facilities management, and scheduling. He is also experienced in process/plant engineering from API (media processing, fermentation, purification) to filling & freeze drying (finishing). Additional skills and experience in Supply Chain Management and tech transfer projects.
Before joining JHL, Henry worked for 3 years as Project Manager of the Project Engineering Group with Bayer Healthcare in California. Prior to Bayer Healthcare, he worked for Genentech and has over 20 years of experience in pharmaceutical industry.
Henry received a B.S. of Chemical Engineering from San Jose State University and B.S. of Biochemistry from University of California, Riverside.